NasdaqCM · Biotechnology

Elicio Therapeutics (ELTX)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+442.8%

$16.50 average target

$3.04-0.04 (-1.1%)Latest market snapshot · Yahoo Finance

Market cap$79.9M

Cash$23.5M

Quarterly burn$11.6M

Pipeline assets3

Short float8.6%

Clinical portfolio

Elicio Therapeutics Drug Pipeline

Showing 1 of 3

Asset	Indication	Stage	Milestone	Signals ?
ELI-002 7P	Pancreatic cancer, Cancer	Phase 3	TBA	—

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

ELTX Catalyst Timeline

1 currently tracked

TBA

ELI-002 7P

Phase 3

Pancreatic cancer, Cancer

Initiation

Event details

Company profile

About Elicio Therapeutics

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.